Global Life Science Business Partnering (GLSBP)

Highlights of November 2022

Gland Pharma buys Cenexi Group for €120 Million.
Mankind Pharma acquires majority stake in Upakarma Ayurveda.
Lupin's Brazilian Subsidiary, MedQuimica Acquires Rights to Nine Brands from Bausch Health.
Aurobindo unit, Evive Biotech ink pact to sell CIN treatment product in US.
SS Innovations acquires controlling interest in US-based Avra Medical Robotics.
Intas enters into an exclusive license agreement with Syna to commercialize LB-0702 in global markets.
Sun Pharma inks licensing pact with SPARC to commercialise benzyl alcohol and propylene glycol-free phenobarbital sodium powder for injection in US market.
Indivior inks $145 Million Opiant buyout to add nasal opioid overdose drug to portfolio.
Jnana Therapeutics inks second collaboration with Swiss giant Roche.
Ono and Captor collaborate in neurodegenerative diseases.
POINT and Lantheus agree licensing deal for novel radiopharmaceuticals.
Oramed inks deal with Medicox for oral insulin in South Korea.
Ocuphire inks license deal with Famy for Nyxol eye drops.
Kissei Pharmaceutical has entered into a license agreement with Synmosa Biopharma for the development and commercialization rights in Taiwan for the GnRH antagonist linzagolix that was discovered by Kissei.

Updates at Aagami:

Aagami team - CEO Dinesh Jain and VP Godwyn Francis to visit Republic of Korea Dec 04-10, as a part of the State of Illinois Trade Delegation to Seoul, Korea.

INFOCUS: Select opportunities available at Aagami:

For Partnering/Licensing/ Investment:

Technology Licensing: Easy to apply Microneedle Array Patch (MAP) system to deliver drugs, vaccines; better immune response than injection. A painless and efficient replacement to Syringes.
Midwest US based Pharma’s First-in-Class Non-Opioid Analgesic for both chronic and acute Pain Relief – Seeking funding/licensing/co-development partnerships.
Investment / Licensing - US FDA approved portable MRI Guided Treatment, Diagnosis and Screening ($40 Million Series C Open). For Urology applications.
Series B Open- Novel Evolution of Portable MRI and Robotics for Neurology treatments like Strokes and TBI.

For Acquisition:

Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics and substantial returns.